Dr. Uher is Canada Research Chair in Early Intervention in Psychiatry and Member of the Brain Repair Centre at the Dalhousie University, Halifax, NS, and clinical lecturer in affective disorders at King’s College London, UK. Dr Uher completed medical studies and PhD at the Charles University in Prague and trained in psychiatry at the Maudsley Hospital, London. His primary interests are early interventions to prevent severe mental illness, classification of psychopathology, the treatment of depression, the use of clinical assessment and genomics to personalize and optimize treatment and the interplay of genes and environment in the causation of mental illness.
Roy Perlis, MD, MSc is the Director of the Center for Experimental Drugs and Diagnostics (CEDD) and Associate Director of the Psychiatric Genetics Program in Mood and Anxiety Disorders in the PGH Psychiatry Department. He is an Associate Professor of Psychiatry at Harvard Medical School and serves as a consultant to the American Psychiatric Association’s bipolar treatment guidelines workshop. He graduated from Brown University, Harvard Medical School and Harvard School of Public Health, and he completed his residency, chief residency, and clinical/research fellowship at MGH before joining the faculty. Dr. Perlis’ research and clinical work is focused on treatment resistant mood disorders, including bipolar disorder and major depressive disorder. Current research efforts include identifying genetic variations in populations with mental health disorders, exploring variations that might predict treatment response or other behaviors, and developing cost-effective methods for future genetics research using algorithms to search medical record databases.
Karim Malki holds graduate and postgraduate degrees in mechanical engineering, psychology and genetic psychiatry. Karim has trained under the supervision of Dr. Uher and is currently based at the Institute of Psychiatry, SGDP centre, King’s College London. His current work is centered on developing a machine learning based instrument that uses a patient unique genomic signature to predict response outcome to antidepressant medication.
The work on the online calculator has received support from the Innovative Medicine Initiative Joint Undertaking (IMI-JU) under grant agreement n° 115008 of which resources are composed of European Union and the European Federation of Pharmaceutical Industries and Associations (EFPIA) in-kind contribution and financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013). Further information is available at http://www.newmeds-europe.com/